Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DRGT
Dublin, Irelanddrgt.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
DRGT (Drug Rediscovery and Genetic Targeting) is a specialty pharmaceutical company that utilizes its proprietary Super-API technology to improve the clinical performance of established drug compounds. By enhancing the solubility and bioavailability of poorly soluble drugs, DRGT develops products with faster onset of action and improved safety profiles. The company's lead asset, DRGT-06, is a high-bioavailability formulation of meloxicam designed for the management of acute and chronic pain. DRGT was acquired by Viatris (formerly Mylan) in 2020 to strengthen its portfolio of complex therapeutics and pain management solutions.
- Therapeutic areas
- RheumatologyImmunologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Viatris
Beyond the preview
Go deeper on DRGT.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DRGT.